Abstract
Introduction
The concentration of a pharmaceutical found in the environment is determined by the amount used by the patient, the excretion and metabolism pattern, and eventually by its persistence. Biological degradation or persistence of a pharmaceutical is experimentally tested rather late in the development of a pharmaceutical, often shortly before submission of the dossier to regulatory authorities.
Materials and methods
To investigate whether the aspect of persistence of a compound could be assessed early during drug development, we investigated whether biodegradation of pharmaceuticals could be predicted with the help of in silico tools. To assess the value of in silico prediction, we collected results for the OECD 301 degradation test (“ready biodegradability”) of 42 drugs or drug synthesis intermediates and compared them to the prediction of the in silico tool BIOWIN.
Results and discussion
Of these compounds, 38 were predictable with BIOWIN, which is a module of the Estimation Programs Interface (EPI) Suite™ provided by the US EPA. The program failed to predict the two drugs which proved to be readily biodegradable in the degradation tests. On the other hand, BIOWIN predicted two compounds to be readily biodegradable which, however, proved to be persistent in the test setting.
Conclusion
The comparison of experimental data with the predicted one resulted in a specificity of 94% and a sensitivity of 0%. The results of this study do not indicate that application of the biodegradation prediction tool BIOWIN is a feasible approach to assess the ready biodegradability during early drug development.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adler P, Steger-Hartmann T, Kalbfus W (2001) Distribution of natural and synthetic steroid hormones in water samples from Southern and Middle Germany. Acta Hydrochim Hydrobiol 29(4):227–241
Boethling RS, Lynch DG, Jaworska JS, Tunkel JL, Thom GC, Webb S (2004) Using BIOWIN, Bayes and batteries to predict ready biodegradability. Environ Toxicol Chem 23(4):911–920
EMEA. Guideline on environmental risk assessment of medicinal products for human use. CPMP/SWP/4447/00, London, June 2006.
European Commission (1997a) Classification, packaging and labelling of dangerous substances in the European Union. Part 2—testing methods. Part C. 4-B—modified OECD screening test. European Commission, Luxembourg, pp 310–314
European Commission (1997b) Classification, packaging and labeling of dangerous substances in the European Union. Part 2—testing methods. Part C.4-C—carbon dioxide evolution test. European Commission, Luxembourg, pp 315–319
Gerike G, Fischer WK (1979) A correlation study in biodegradability determinations with various chemicals in various tests. Ecotoxicol Environ Saf 3:159–173
Idée JM, Port M, Raynal I, Schaefer M, LeGreneur S, Corot C (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563–576
Informationsdienst Wissenschaft: 1st international conference on Sustainable Pharmacy; http://idw-online.de/pages/de/event22661 (last accessed: Dec 2009).
Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Dsic 4:206–220
Kümmerer K (2007) Sustainable from the very beginning: rational design of molecules by life cycle engineering as an important approach for green pharmacy and green chemistry. Green Chem 9:899–907
Management Strategies for Pharmaceuticals in Drinking Water—website of the START project; http://www.start-project.de/downloads/start_Flyer_neu.pdf (last accessed: Dec 2009).
McFarland MJ (Chair). Science Advisory Board (SAB) Review of the Estimation Programs Interface Suite (EPI Suite™); U.S. Environmental Protection Agency, September 7, 2007.
Neubert C, Länge R, Steger-Hartmann T (2008) In: Aga DS (ed) Gadolinium containing contrast agents for magnetic resonance imaging (MRI)—investigations on the environmental fate and effects. In: fate of pharmaceuticals in the environment and in water treatment systems. CRC Press Taylor & Francis Group, Boca Raton, p 102
OECD guidelines for testing of chemicals. Ready biodegradability: no. 301. adopted 17 Jul. 1992.
OECD guidelines for testing of chemicals (1993a) Ready biodegradability: no. 301E. “Modified OECD screening test”, adopted 17 Jul. 1992. OECD, Paris.
OECD guidelines for testing of chemicals (1993b) Ready biodegradability: no. 301B. “CO2 evolution test”, adopted 17 Jul. 1992. OECD, Paris.
OECD guidelines for testing of chemicals (1993c) Ready biodegradability: no. 301 F. “Manometric Respiration Test”, adopted 17 Jul 1992. OECD, Paris.
Oprea TI (2002) Current trends in lead discovery: are we looking for the appropriate properties? J Comp Aided Des 16:325–334
Steger-Hartmann T (2004) In: Reichl FX, Schwenk M (eds) Computer-gestützte Vorhersagesysteme. In: Regulatorische Toxikologie. Springer, Berlin, p 97
Steger-Hartmann T, Länge R, Schweinfurth H, Tschampel M, Rehmann I (2002) Investigations into the environmental fate and effects of iopromide (Ultravist), a widely used iodinated X-ray contrast medium. Water Res 36:266–274
US Environmental Protection Agency website on green chemistry; http://www.epa.gov/greenchemistry/ (last accessed: Dec 2009).
Weber S, Leuschner P, Kämpfer P, Dott W, Hollender J (2005) Degradation of estradiol and ethinyl estradiol by activated sludge and by a defined mixed culture. Appl Microbiol Biotechnol 67:106–112
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible editor: Philippe Garrigues
Rights and permissions
About this article
Cite this article
Steger-Hartmann, T., Länge, R. & Heuck, K. Incorporation of in silico biodegradability screening in early drug development—a feasible approach?. Environ Sci Pollut Res 18, 610–619 (2011). https://doi.org/10.1007/s11356-010-0403-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11356-010-0403-2